新型冠状病毒2型（SARS-CoV-2）仍在迅速传播。未找到有关石仙桃（Thesium chinense Turcz，列当科）抗病毒效果的相关研究。为了研究石仙桃提取物的抗病毒和抗炎效果，本研究旨在探讨不同浓度（80、160、320、640、960 μg/mL）酒精提取物对SARS-CoV-2的抗入侵和复制效应。阳性对照组使用Remdesivir（20.74 μM），宿主细胞采用Vero细胞，通过实时定量聚合酶链反应（RT-PCR）和Western blotting检测病毒核衣壳蛋白（NP）的表达水平。使用RAW264.7细胞作为抗炎实验模型，并在脂多糖（LPS）刺激下检测肿瘤坏死因子-α（TNF-α）和白细胞介素-6（IL-6）的表达水平，以研究酒精提取物对其的影响。石仙桃酒精提取物显著抑制了SARS-CoV-2在Vero细胞中的复制（半最大有效浓度，EC50: 259.3 μg/mL）和入侵（EC50: 359.1 μg/mL），并显著降低了LPS刺激下RAW264.7细胞产生的IL-6和TNF-α水平。石仙桃的石油醚（EC50: 163.6 μg/mL），乙酸乙酯（EC50: 22.92 μg/mL）和正丁醇（EC50: 56.8 μg/mL）提取物对SARS-CoV-2在Vero细胞中的复制有较弱的抑制作用，并能够降低LPS刺激下RAW264.7细胞产生的IL-6和TNF-α水平。因此，石仙桃可能是抗击SARS-CoV-2的潜在候选药物，且正在成为治疗COVID-19的中药候选物。

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still spreading rapidly. Relevant research based on the antiviral effects of Thesium chinense Turcz (Santalaceae) was not found.To investigate the antiviral and anti-inflammatory effects of extracts of T. chinense.To investigate the anti-entry and replication effect of the ethanol extract of T. chinense (drug concentration 80, 160, 320, 640, 960 μg/mL) against the SARS-CoV-2. Remdesivir (20.74 μM) was used as positive control, and Vero cells were used as host cells to detect the expression level of nucleocapsid protein (NP) in the virus by real-time quantitative polymerase chain reaction (RT-PCR) and Western blotting. RAW264.7 cells were used as an anti-inflammatory experimental model under lipopolysaccharide (LPS) induction, and the expression levels of tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) were detected by enzyme-linked immunosorbent assay (ELISA).The ethanol extract of T. chinense significantly inhibited the replication (half maximal effective concentration, EC50: 259.3 μg/mL) and entry (EC50: 359.1 μg/mL) of SARS-CoV-2 into Vero cells, and significantly reduced the levels of IL-6 and TNF-α produced by LPS-stimulated RAW264.7 cells. Petroleum ether (EC50: 163.6 μg/mL), ethyl acetate (EC50: 22.92 μg/mL) and n-butanol (EC50: 56.8 μg/mL) extracts showed weak inhibition of SARS-CoV-2 replication in Vero cells, and reduced the levels of IL-6 and TNF-α produced by LPS-stimulated RAW264.7 cells.T. chinense can be a potential candidate to fight SARS-CoV-2, and is becoming a traditional Chinese medicine candidate for treating COVID-19.